Annovis Bio Inc (ANVS) Stock Forecast & Price Target
Annovis Bio Inc · NYSE
$1.30-0.09 (-6.12%)
15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering Annovis Bio Inc, 2 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets range widely, $7.00 to $17.00 (about 2.4x), a sign of real disagreement on valuation. The average target of $12.00 sits 820% above the current $1.30. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near 0% this year and 0% next, consensus EPS building from about $-0.23 next quarter toward $-0.86 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Strong Buy
Strong Buy00%
Buy2100%
Hold00%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to Annovis Bio Inc.
As of Sep, 2 of 2 firms rate ANVS a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ANVS EPS & revenue forecast
EPS · NEXT QUARTER
$-0.23
Range $-0.30 – $-0.17 · 2 analysts · -40% YoY
Next period, 2 analysts expect Annovis Bio Inc to earn $-0.23 a share (range $-0.30 – $-0.17), versus $-0.39 a year earlier. Full-year consensus is $-1.45, growing to $-0.86 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 2 analysts · +0% YoY
Revenue is expected to reach $0 (range $0 – $0), +0.0% year-over-year. Full-year consensus is $0, rising to $0 next year.
Top analysts covering Annovis Bio Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ANVS.
#1
Sumant Kulkarni
Canaccord Genuity · Rank #293
Buy
$17.00+1202.7% to target
Overall win rate
41%
+ Follow
#2
Raghuram Selvaraju
HC Wainwright & Co. · Rank #312
Buy
$10.00+666.3% to target
Overall win rate
36%
+ Follow
#3
Jason Kolbert
D. Boral Capital · Rank #416
Hold
No targeton ANVS
Overall win rate
22%
+ Follow
#4
Jason McCarthy
Maxim Group · Rank #428
Buy
$25.00+1815.7% to target
Overall win rate
32%
+ Follow
#5
Boobalan Pachaiyappan
Roth Capital
Buy
$7.00+436.4% to target
Coverage
—
+ Follow
ANVS stock forecast FAQ
What is ANVS's average 12-month price target?+
The 2 analysts with a live target average $12.00 for Annovis Bio Inc over the next 12 months, ranging from a $17.00 high to a $7.00 low.
Is ANVS stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 2 analyst ratings, 2 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ANVS?+
The Street-high target is $17.00 (Canaccord Genuity), and the Street-low is $7.00 (Roth Capital). The average of all 2 active targets is $12.00.
How many Wall Street analysts cover ANVS?+
2 analysts have an active rating on Annovis Bio Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering ANVS?+
Among analysts who currently cover ANVS, Sumant Kulkarni of Canaccord Genuity has the strongest overall Quantellect track record (Rank #293). Their current call is Buy with a $17.00 target.
What is Annovis Bio Inc's projected EPS for next quarter?+
The consensus estimate is $-0.23 per share (range $-0.30 – $-0.17) across 2 analysts. Full-year EPS is projected at $-1.45, rising to $-0.86 the following year.
How much revenue is Annovis Bio Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading ANVS lately?+
As of Sep, 2 of 2 firms rate ANVS a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ANVS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
